# A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

> **NCT07285304** · PHASE3 · RECRUITING · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Hyperphosphatemia Patients on Hemodialysis

## Interventions

- **DRUG:** TS-172

## Key facts

- **NCT ID:** NCT07285304
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285304, "A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07285304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*